JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

Search

Day One Biopharmaceuticals Inc

Cerrado

SectorSalud

11.35 8.3

Resumen

Variación precio

24h

Actual

Mínimo

10.48

Máximo

11.49

Métricas clave

By Trading Economics

Ingresos

11M

-20M

Ventas

5.9M

40M

Margen de beneficio

-49.569

Empleados

184

EBITDA

16M

-19M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+112.69% upside

Dividendos

By Dow Jones

Próximas Ganancias

24 feb 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

432M

1.2B

Apertura anterior

3.05

Cierre anterior

11.35

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

151 / 352 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Day One Biopharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

6 feb 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

6 feb 2026, 21:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

6 feb 2026, 21:40 UTC

Adquisiciones, fusiones, absorciones

Verizon Insiders Rarely Sell Company Stock. This Insider Just Did. -- Barrons.com

6 feb 2026, 21:22 UTC

Charlas de Mercado

Mexico's Inflation Seen Accelerating in January -- Market Talk

6 feb 2026, 21:17 UTC

Ganancias

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6 feb 2026, 21:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

6 feb 2026, 21:14 UTC

Adquisiciones, fusiones, absorciones

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- Update

6 feb 2026, 21:13 UTC

Ganancias

How the Software Panic Hit BDC Stocks -- and Why Some Might Be Worth Buying -- Barrons.com

6 feb 2026, 21:13 UTC

Ganancias

Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More Stock Market Movers -- Barrons.com

6 feb 2026, 21:04 UTC

Charlas de Mercado

Gold Closes Out Volatile Week on Higher Note -- Market Talk

6 feb 2026, 20:34 UTC

Ganancias

Tech Had an Awful Earnings Season. Other Stocks Are Saving the Day. -- Barrons.com

6 feb 2026, 20:27 UTC

Ganancias

These Stocks Are Today's Movers: Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More -- Barrons.com

6 feb 2026, 20:24 UTC

Charlas de Mercado

Oil Futures Settle Higher As U.S.-Iran Talks Get Under Way -- Market Talk

6 feb 2026, 20:20 UTC

Charlas de Mercado

U.S. Natural Gas Futures Retreat Ahead of Weekend -- Market Talk

6 feb 2026, 19:48 UTC

Ganancias

Take-Two, Mondelez Get Analyst Attention -- Barrons.com

6 feb 2026, 19:30 UTC

Adquisiciones, fusiones, absorciones

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- WSJ

6 feb 2026, 19:30 UTC

Adquisiciones, fusiones, absorciones

Justice Department Asking Industry How Netflix or Paramount Deal for Warner Bros. Might Impact Competition, According to Subpoena -- WSJ

6 feb 2026, 19:30 UTC

Adquisiciones, fusiones, absorciones

DOJ Asking if Netflix Engaged in 'Exclusionary Conduct' That May Lead to Monopoly, According to Subpoena -- WSJ

6 feb 2026, 19:17 UTC

Charlas de Mercado

USDA Says Farm Income to Decrease in 2026 -- Market Talk

6 feb 2026, 18:50 UTC

Ganancias

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6 feb 2026, 18:47 UTC

Charlas de Mercado

Natural Gas-Infrastructure Operators Take 'Flight to Scale' -- Market Talk

6 feb 2026, 18:34 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises By 1 to 412 -- Market Talk

6 feb 2026, 17:58 UTC

Ganancias

Reddit Stock Falls After Strong Earnings. Wall Street Is Debating What's Next. -- Barrons.com

6 feb 2026, 17:52 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

6 feb 2026, 17:52 UTC

Charlas de Mercado
Ganancias

Amazon's CapEx Seen as Misunderstood by Investors -- Market Talk

6 feb 2026, 17:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

6 feb 2026, 17:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

6 feb 2026, 17:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

6 feb 2026, 17:18 UTC

Charlas de Mercado

Canada's Bizarre Jobs Report Points to Growing Labor Slack -- Market Talk

6 feb 2026, 17:09 UTC

Charlas de Mercado

Dollar on Path to Snap Weekly Losing Streak -- Market Talk

Comparación entre iguales

Cambio de precio

Day One Biopharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

112.69% repunte

Estimación a 12 meses

Media 22.29 USD  112.69%

Máximo 29 USD

Mínimo 16 USD

De acuerdo con 9 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Day One Biopharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

9 ratings

8

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

6.26 / 7.47Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

151 / 352 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
help-icon Live chat